Overview

Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

Status:
Completed
Trial end date:
2013-11-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if enzalutamide is an effective therapy in treating localized prostate cancer prior to prostatectomy.
Phase:
Phase 2
Details
Lead Sponsor:
Medivation, Inc.
Pfizer
Collaborators:
Astellas Pharma Inc
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Treatments:
Dutasteride
Leuprolide